Article Sidebar

Submitted
November 11, 2024
Accepted
November 11, 2024
Published
November 11, 2024
Download
PDF
Statistic
Read Counter : 524 Download : 309

Main Article Content

Abstract

Background: On the first day of the SARS-CoV2 pandemic, azithromycin (AZM) was one of
the most commonly utilised drugs, even though there is no scientific evidence to support its
usage in treating COVID-19. Because it encourages the establishment of drug-resistant bacterial
strains, which makes it more tough to successfully treat a range of bacterial infections, its free
egress has generated worries about public health. Perfect for learning how to combat COVID-19
infections using antibiotics that are effective against azole-group fever (AZM)-resistant bacteria.
Methods: In order to mimic cases of tonsillitis, pharynx infections, or respiratory tract
infections, a control group consisting of 25 samples were used from healthy individuals as a
control group and 37 bacterial isolates was maintained apart from cases that had previously
contracted the corona virus. Ten scholarly articles were completely reviewed. All extra criteria
were met by studies published between 2015 and 2023 that dealt with AZM resistance in bacteria
during the treatment of bacteriosis or the fight against COVID-19.
Results: indicated that out of 25 control samples, 13 (or 52% of the total) responded positively
to AZM whereas 12 (or 48% of the total) were resistant. In addition, 26 (70.27%) of the bacteria
that were isolated were completely resistant to the antibiotic, whereas 11 (29.72%) of the isolates
were found to be susceptible.
Conclusions: Implicit bacterial resistance to AZM is directly correlated with the careless use
of this medication. Because AZM, an antibiotic drug, is widely used to treat a variety of bacterial
diseases, the emergence of resistance bacteria poses a significant threat to public health.

Keywords

COVID-19 drug resistance Azithromycin Antibacterial

Article Details

License

Copyright (c) 2024 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Park, S. E. (2020). Epidemiology, virology, and clinical features of severe acute
  2. respiratory syndrome-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clinical and
  3. experimental pediatrics, 63(4), 119. doi: 10.3345/cep.2020.00493
  4. Yüce, M., Filiztekin, E., & Özkaya, K. G. (2021). COVID-19 diagnosis—A review of
  5. current methods. Biosensors doi.org/10.1016/j.bios.2020.112752
  6. and Bioelectronics, 172, 112752. Sultana, J., Cutroneo, P. M., Crisafulli, S., Puglisi, G., Caramori, G., & Trifirò, G.
  7. (2020). Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and
  8. prescribing guidelines. Drug safety, 43, 691-698. doi.org/10.1007/s40264-020-00976-7
  9. Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. (2015). Molecular mechanisms of antibiotic resistance. Nature reviews microbiology, 13(1), 42-51. doi.org/10.1038/nrmicro3380
  10. Ranjbar, R., & Alam, M. (2024). Antimicrobial Resistance Collaborators (2022).
  11. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. EvidenceBased Nursing, 27(1), 16-16. doi.org/10.1136/ebnurs-2022-103540
  12. Wahab, S., Ahmad, M. F., Hussain, A., Usmani, S., Shoaib, A., & Ahmad, W. (2021).
  13. Effectiveness of Azithromycin as add-on Therapy in COVID-19 Management. Mini Reviews in
  14. Medicinal Chemistry, 21(19), 2860-2873. doi.org/10.2174/1389557521666210401093948.
  15. Bakheit, A. H., Al-Hadiya, B. M., & Abd-Elgalil, A. A. (2014). Azithromycin. Profiles of drug substances, excipients doi.org/10.1016/B978-0-12-800173-8.00001-5
  16. and related methodology, 39, 1-40. Heidary, M., Ebrahimi Samangani, A., Kargari, A., Kiani Nejad, A., Yashmi, I., Motahar, M., ... & Khoshnood, S. (2022). Mechanism of action, resistance, synergism, and clinical implications of azithromycin. Journal of clinical laboratory analysis, 36(6), e24427. doi.org/10.1002/jcla.24427
  17. Chiou, C. S., Hong, Y. P., Wang, Y. W., Chen, B. H., Teng, R. H., Song, H. Y., &
  18. Liao, Y. S. (2023). Antimicrobial resistance and mechanisms of azithromycin resistance in
  19. nontyphoidal Salmonella isolates in Taiwan, 2017 to 2018. Microbiology spectrum, 11(1),
  20. e03364-22. doi: 10.1128/spectrum.03364-22. Epub 2023 Jan 23.
  21. Majumder, M. A. A., Rahman, S., Cohall, D., Bharatha, A., Singh, K., Haque, M., & Gittens-St Hilaire, M. (2020). Antimicrobial stewardship: fighting antimicrobial resistance and protecting global public health. Infection and drug resistance, 4713-4738. doi: 10.2147/IDR.S290835
  22. Parnham, M. J., Haber, V. E., Giamarellos-Bourboulis, E. J., Perletti, G., Verleden, G. M., & Vos, R. (2014). Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacology 10.1016/j.pharmthera.2014.03.003.
  23. & therapeutics, 143(2),
  24. -245. doi: Unemo, M., Golparian, D., & Eyre, D. W. (2019). Antimicrobial resistance in Neisseria gonorrhoeae and treatment of gonorrhea. Neisseria gonorrhoeae: methods and protocols, 37-58. doi: 10.1007/978-1-4939-9496-0_3.
  25. Doan, T., Worden, L., Hinterwirth, A., Arzika, A. M., Maliki, R., Abdou, A., ... &
  26. Lietman, T. M. (2020). Macrolide and nonmacrolide resistance with mass azithromycin
  27. distribution.
  28. New England Journal of Medicine, 383(20), 1941-1950. doi:
  29. 1056/NEJMoa2002606.
  30. Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C.
  31. G., ... & Monnet, D. L. (2012). Multidrug-resistant, extensively drug-resistant and pandrug
  32. resistant bacteria: an international expert proposal for interim standard definitions for acquired
  33. resistance. Clinical microbiology and infection, 18(3), 268-281. doi: 10.1111/j.1469
  34. 2011.03570.x.
  35. Kuleshova, S. I., Protsak, S. A., Lisunova, S. A., & Romanyuk, G. Y. (2021). Stability
  36. of ready-to-use and laboratory-prepared culture media. Regulatory Research and Medicine
  37. Evaluation, 11(2), 130-134. doi.org/10.30895/1991-2919-2021-11-2-130-134
  38. Tibbits, G., Mohamed, A., Call, D. R., & Beyenal, H. (2022). Rapid differentiation of
  39. antibiotic-susceptible and-resistant bacteria through mediated extracellular electron transfer.
  40. Biosensors and Bioelectronics, 197, 113754. doi: 10.1016/j.bios.2021.113754.
  41. Huemer, M., Mairpady Shambat, S., Brugger, S. D., & Zinkernagel, A. S. (2020).
  42. Antibiotic resistance and persistence—Implications for human health and treatment perspectives.
  43. EMBO reports, 21(12), e51034. doi: 10.15252/embr.202051034.
  44. Larsson, D. G., & Flach, C. F. (2022). Antibiotic resistance in the environment. Nature
  45. Reviews Microbiology, 20(5), 257-269. doi: 10.1038/s41579-021-00649-x.
  46. Miranda, C., Silva, V., Capita, R., Alonso-Calleja, C., Igrejas, G., & Poeta, P. (2020).
  47. Implications of antibiotics use during the COVID-19 pandemic: present and future. Journal of
  48. Antimicrobial Chemotherapy, 75(12), 3413-3416. doi: 10.1093/jac/dkaa350.
  49. Rufino, J. P., Sousa, L. G. V., Rodrigues, A. E. L., Falcão, A. L. S., de Melo Lima, I.
  50. C., de Miranda Cavalcanti, L. A., ... & de Oliveira Filho, J. W. G. (2022). Bacterial resistance to
  51. azithromycin: causes, effects, and the fight against COVID-19. Research, Society and
  52. Development, 11(6), e27711629198-e27711629198. doi.org/10.33448/rsd-v11i6.29198
  53. Crespi, E., Pereyra, A. M., Puigdevall, T., Rumi, M. V., Testorelli, M. F., Caggiano,
  54. N., ... & Srednik, M. E. (2022). Antimicrobial resistance studies in staphylococci and
  55. streptococci isolated from cows with mastitis in Argentina. Journal of Veterinary Science, 23(6).
  56. doi: 10.4142/jvs.21062.
  57. Mupfunya, C. R., Qekwana, D. N., & Naidoo, V. (2021). Antimicrobial use practices
  58. and resistance in indicator bacteria in communal cattle in the Mnisi community, Mpumalanga,
  59. South Africa. Veterinary Medicine and Science, 7(1), 112-121. doi: 10.1002/vms3.334.
  60. Septimus, E. J. (2018). Antimicrobial resistance: an antimicrobial/diagnostic
  61. stewardship and infection prevention approach. Medical Clinics, 102(5), 819-829. doi:
  62. 1016/j.mcna.2018.04.005.
  63. Christaki, E., Marcou, M., & Tofarides, A. (2020). Antimicrobial resistance in
  64. bacteria: mechanisms, evolution, and persistence. Journal of molecular evolution, 88(1), 26-40.
  65. doi: 10.1007/s00239-019-09914-3.
  66. Retallack, H., Di Lullo, E., Arias, C., Knopp, K. A., Laurie, M. T., Sandoval-Espinosa,
  67. C., ... & DeRisi, J. L. (2016). Zika virus cell tropism in the developing human brain and
  68. inhibition by azithromycin. Proceedings of the National Academy of Sciences, 113(50), 14408
  69. doi: 10.1073/pnas.1618029113.
  70. Singh, N., Tang, Y., Zhang, Z., & Zheng, C. (2020). COVID-19 waste management:
  71. Effective and successful measures in Wuhan, China. Resources, conservation, and recycling,
  72. , 105071. doi: 10.1016/j.resconrec.2020.105071.
  73. Sulayyim, H. J. A., Ismail, R., Hamid, A. A., & Ghafar, N. A. (2022). Antibiotic
  74. resistance during COVID-19: a systematic review. International journal of environmental
  75. research and public health, 19(19), 11931. doi: 10.3390/ijerph191911931.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)